Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 3/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL546625 | 0.94 | SSTR4 (0.39) | SSTR4CD274ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14163870 | 0.84 | CD274 (0.40) | CD274ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL12027365 | 0.83 | MAPK1 (0.39) | CD274ALDH1A1KDM4ESMN1; SMN2HPGD | |
| SCHEMBL546463 | 0.82 | ITK (0.38) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL546124 | 0.80 | EPHA2 (0.39) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL1644923 | 0.79 | KDM4E (0.41) | KDM4E | |
| SCHEMBL12582697 | 0.79 | KDM4E (0.41) | KDM4E | |
| SCHEMBL1645725 | 0.79 | KDM4E (0.45) | ALDH1A1KDM4EHSD17B10POLBTSHR | |
| SCHEMBL8302949 | 0.79 | KDM4E (0.45) | ALDH1A1KDM4EHSD17B10POLBTSHR | |
| SCHEMBL14780757 | 0.79 | KDM4E (0.45) | ALDH1A1KDM4EHSD17B10POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778936-B2 | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8778936-B2 | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8399442-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399442-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| US-8110573-B2 | Enzyme inhibitors; Cyclin-Dependent Kinases (CDK), Glycogen Synthase Kinases (GSK); -cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea salt for example; anticancer agents | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-07 | — | — | US | disclosed |
| US-8110573-B2 | Enzyme inhibitors; Cyclin-Dependent Kinases (CDK), Glycogen Synthase Kinases (GSK); -cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea salt for example; anticancer agents | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-07 | — | — | US | disclosed |
| EP-2395000-A1 | Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases | Astex Therapeutics Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| WO-2007077435-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | SSTR4 3892/4885CD274 676/4885ALDH1A1 3042/4885 |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK3, CDK1, AURKA | SSTR4 4643/4885CD274 2652/4885ALDH1A1 3717/4885 |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | CDK3, CDK1, AURKA | SSTR4 4643/4885CD274 2652/4885ALDH1A1 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.